🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "major milestone" in the effort against superbug strains of the infection, according to health experts.

An International Challenge

Gonorrhoea infections are on the rise around the world, with estimates suggesting over 82 million infections annually. Particularly high rates are reported in the African continent and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary step in the reality of increasing worldwide cases, escalating drug resistance and the extremely scarce therapeutic options currently available.”

Public health authorities are increasingly worried about the increase in treatment-resistant strains. The WHO has designated it as a "priority pathogen". A tracking program showed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Receive Authorization

One new antibiotic, also known as Nuzolvence, was cleared by the US FDA in mid-December for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Researchers hope that specific application of this new drug will help hinder the development of resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, was also approved in close succession. This treatment, which is also used to treat UTIs, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment was the result of a unique collaborative effort for medication research. The non-profit organisation GARDP collaborated with the drug firm its industry partner to develop it.

“This milestone signifies a significant shift in the treatment of highly resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Clinical Trial Outcomes and Global Access

Based on data detailed in a prominent scientific publication, zoliflodacin eradicated over nine in ten of genital gonorrhoea infections. This establishes an similar efficacy with the typical regimen, which uses an injection and a pill. The study involved over 900 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the authority to license and sell the drug in many developing nations.

Clinicians treating patients have shared hope. Access to a single-dose, oral treatment such as this is described as a "revolutionary step" for managing the epidemic. This is deemed crucial to lessen the impact of the illness for people and to prevent the spread of extremely resistant gonorrhoea worldwide.